Vivos TherapeuticsVVOS
13F holders, Q4 2025 (December 31)19holders −4
1new positions
5sold out
$2.03avg. 13F price*
At the end of Q4 2025, 19 institutions reported holding Vivos Therapeutics Inc. (VVOS) in their 13F filings, down 4 from Q3 2025. 1 opened new positions and 5 sold out. The largest holders were Vanguard Group Inc. ($617K), DRW Securities, LLC ($235K) and Geode Capital Management, LLC ($114K).
- Company
- Vivos Therapeutics Inc.
- CUSIP
- 92859E207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $30K |
| Exits | 5 | $1.1M |
All 13F filers, Q3 2025 → Q4 2025: 317,676 shares bought and 346,310 shares sold, net −28,634 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| Vanguard Group Inc. | 0.00% | Add +232.6% | 304,161 | $617K |
| DRW Securities, LLC | 0.02% | Add +179.5% | 115,907 | $235K |
| Geode Capital Management, LLC | 0.00% | Add +5.6% | 56,287 | $114K |
| B. Riley Wealth Advisors, Inc. | 0.00% | No change | 43,531 | $88K |
| Commonwealth Equity Services, LLC | 0.00% | Reduce -1.2% | 40,500 | $82K |
| BlackRock, Inc. | 0.00% | No change | 27,817 | $56K |
| State Street Corp. | 0.00% | No change | 24,922 | $51K |
| Acorn Wealth Advisors, LLC | 0.01% | New | 14,776 | $30K |
| UBS Group AG | 0.00% | Add +12328.4% | 12,677 | $26K |
| Northern Trust Corp. | 0.00% | No change | 12,511 | $25K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +6.1% | 2,965 | $6K |
| Osaic Holdings, Inc. | 0.00% | Reduce -82.6% | 1,143 | $2K |
| Signaturefd, LLC | 0.00% | No change | 547 | $1K |
| Blue Trust, Inc. | 0.00% | No change | 160 | $325 |
| Bank of America Corp. | 0.00% | Add +12.8% | 132 | $267 |
| Kozak & Associates, Inc. | 0.00% | No change | 49 | $101 |
| Morgan Stanley | 0.00% | Reduce -99.3% | 7 | $14 |
| Citigroup Inc. | 0.00% | No change | 1 | $2 |
| Royal Bank of Canada | 0.00% | No change | 4 | $0 |
"% of holder's portfolio" is VVOS's weight in each manager's 13F, not the share of Vivos Therapeutics Inc. the manager owns.